Skip to main content
Midas Edge

Olema Pharmaceuticals, Inc.

For the period ended Jun 30, 2025. Filed Aug 11, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 11, 2025

OLMA$7.27-1.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders’ Equity

Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)

Accumulated
Additional · Other · Total
Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders'
Shares · Amount · Capital · Income · Deficit · Equity
Balances at March 31, 202568,333,065$7$848,520$420$(465,495)$383,452
Stock-based compensation expense, including employee stock purchase plan expense——4,692——4,692
Issuance of shares under employee stock purchase plan206,609—748——748
Exercise of stock options88,212—234——234
Net unrealized loss on marketable securities———(106)—(106)
Net loss————(43,784)(43,784)
Balances at June 30, 202568,627,886$7$854,194$314$(509,279)$345,236
Accumulated
Additional · Other · Total
Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders'
Shares · Amount · Capital · Income · Deficit · Equity
Balances at December 31, 202474,312,608$7$843,920$143$(435,106)$408,964
Stock-based compensation expense, including employee stock purchase plan expense——9,070——9,070
Issuance of shares under employee stock purchase plan206,609—748——748
Exercise of stock options178,669—470——470
Issuance cost associated with private equity placement——(14)——(14)
Exchange of common stock shares for pre-funded warrants(6,070,000)—————
Net unrealized gain on marketable securities———171—171
Net loss————(74,173)(74,173)
Balances at June 30, 202568,627,886$7$854,194$314$(509,279)$345,236

Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)

Accumulated
Additional · Other · Total
Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders'
Shares · Amount · Capital · (Loss) Income · Deficit · Equity
Balances at March 31, 202455,867,863$4$572,926$(10)(336,602)$236,318
Issuance of shares under at-the-market offering, net of issuance costs of $251,225,952—14,886——14,886
Stock-based compensation expense——5,542——5,542
Issuance of shares under the employee stock purchase plan70,701—650——650
Employee stock purchase plan expense——182——182
Exercise of stock options29,587—75——75
Vesting of restricted stock awards52,308—————
Net unrealized loss on marketable securities———(108)—(108)
Net loss————(30,382)(30,382)
Balances at June 30, 202457,246,411$4$594,261$(118)(366,984)$227,163
Accumulated
Additional · Other · Total
Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders'
Shares · Amount · Capital · (Loss) Income · Deficit · Equity
Balances at December 31, 202354,992,784$4$559,176$347(305,632)$253,895
Issuance of shares under at-the-market offering, net of issuance costs of $1661,772,278—22,787——22,787
Stock-based compensation expense——10,246——10,246
Exercise of stock options317,989—1,015——1,015
Issuance of shares under the employee stock purchase plan70,701—650——650
Employee stock purchase plan expense——387——387
Vesting of restricted stock awards92,659—————
Net unrealized loss on marketable securities———(465)—(465)
Net loss————(61,352)(61,352)
Balances at June 30, 202457,246,411$4$594,261$(118)(366,984)$227,163

Condensed Consolidated Statements of Cash Flows

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.